Journal List > Anat Cell Biol > v.57(3) > 1516088499

Uzomba, Ezemagu, Ofoegbu, Lydia, Goodness, Emelike, Obinna, Nwafor, and Mbajiorgu: Edible mushroom (Pleurotus cornucopiae) extract vs. glibenclamide on alloxan induced diabetes: sub-acute in vivo study of Nrf2 expression and renal toxicity

Abstract

The study aims to compare the action of Pleurotus cornucopiae and glibenclamide on alloxan-induced diabetes and ascertain how an aqueous extract of the edible mushroom regulates the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), oxidative stress biomarkers and renal toxicity in a diabetic male Wistar rat model. Twenty-five adult male Wistar rats were randomly grouped into five groups with five rats per. Group 1 and those in the treatment groups received normal feed and water ad libitum. Group 2 received intraperitoneal administration of alloxan monohydrate (150 mg/kg body weight). Group 3 received alloxan monohydrate and glibenclamide (5 mg/kg body weight bwt), group 4 received alloxan monohydrate plus the extract (250 mg/kg bwt) and group 5 received alloxan monohydrate plus the extract (500 mg/kg bwt). The administration of glibenclamide plus the extract was oral for 14 days. Glibenclamide and the extract lowered blood glucose level, catalase, and glutathione peroxidase activities, increased the superoxide dismutase (SOD) activity in rats with alloxan induced diabetes. The extract at 500 mg/kg bwt reduced the plasma urea and sodium concentration in the treated rats. The extract and glibenclamide could detoxify alloxan and restore its induced renal degeneration and glomeruli atrophy, intra renal hemorrhage and inflammation and oxidative biomarkers through activation of Nrf2 expression. The drug glibenclamide and P. cornucopiae have appreciable hypoglycemic activity and potential to restore the normal renal architecture in the rats, hence they offer similar curative effects. Additionally, the extract at 500 mg/kg bwt activated SOD and Nrf2 expression more than glibenclamide in rats with alloxan-induced diabetes.

Introduction

Diabetes mellitus (DM) is a combination of heterogeneous disorders commonly presenting with episodes of hyperglycaemia and glucose intolerance, as a result of lack of insulin or defective insulin action [1]. DM is one of the most common non-communicable diseases globally and as emerged as a public health burden in sub-Saharan African [2]. It is the leading cause of chronic and end-stage renal disease generally [3]. Although, recent studies emphasized treatment using resistant antibodies [4], it is cost intensive, and often, the diagnostic kits are unavailable in many healthcare facilities in Nigeria and probably in other economically negatively challenged African nations [5]. Approximately 5.8% (about 10 million) of adult Nigerians are living with DM [6, 7]. When some of the diagnostics kits are available, the technical skill of the caregivers of the procedures are often insufficient [6, 8] resulting in very poor glycemic monitoring of fasting glucose level with its attendant consequences. Though, healthcare providers, pharmaceutical industries and policy makers are relentlessly making efforts to make diagnostics kits available, only 15% of diagnosed patient population, visit conventional hospitals for monitoring of their blood glucose levels through routine check-ups. The greater percentage of these patients utilize self-medication, herbal remedies or no medication, which consequently invariably lead to renal damage, impairment and ulcerations, and subsequently disability or death [6, 8]. Therefore, easily available alternative, cheat but efficacious treatment options is highly imperative in such environments or social settings.
In these settings, as in the sub-Saharan region, there are abundant indigenous mushrooms, which are rich in bioactive substances such as flavonoids, saponin, alkaloids, steroids, phenol, tannin, and glycosides [9], and in food nutrients such as; polysaccharides, proteins, peptides, and lectins [10-12]. Furthermore, mushrooms are said to contain anticancer, antibacterial and antiviral agents [13], which could regulate blood glucose, cholesterol levels and inflammation [14-16]. The mushrooms also contain beneficial bioactive substances, high levels of macro and micro food elements that are essential for fluid balance and cellular homeostasis [17], and the regulation of inflammation and blood glucose level [18] as well as acting as an in vitro antioxidant system [19]. Glibenclamide, a conventional drug is used in hyperglycaemic conditions to lower blood glucose through stimulating insulin production from the existing beta cells of pancreas [20, 21].
The study aims to compare the action of Pleurotus cornucopiae and glibenclamide on alloxan induced diabetes, and ascertain how oral administration of an aqueous extract of the edible mushroom (P. cornucopiae) could regulate the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), impacts oxidative stress biomarkers and alloxan induced diabetes kidney damage in diabetic male Wistar rats. It would also profile an in vivo diabetes management protocol, and ascertain the different concentrations of the basic phytochemicals in aqueous extract of P. cornucopiae commonly found in our locality.

Materials and Methods

Mushroom cultivation

The mushroom was cultivated in AE-FUNAI farm on a mixture of appropriate quantities of wood (WD), rice dust (RD) and limestone, and the fruiting was very successful. The quantity of substrate for the cultivation of the mushrooms was calculated using the following measurement as described by Okigbo et al. [22] and modified by addition of more WD and RD by the authors.
1. WD: WD=45 kg, WDC (wood dust constant)=0.64
WD×WDC=45 kg×0.64=28.8 kg
Quantity of WD used=28.8 kg
2. RD: WD (28.8 kg)×RDC (rice dust constant)=0.3
WD×RDC=28.8 kg×0.3=8.64 kg
Quantity of RD used=8.64 kg
3. Limestone: WD+RD×LSC (limestone constant)=0.01
(WD+RD)×LSC=28.8 kg+8.64 kg×0.01=0.374 kg
Quantity of limestone used=0.374 kg
4. Water: WD+RD×WC (water constant)=0.80
(WD+RD)×WC=28.8 kg+8.64 kg×0.80=29.95 L
Quantity of water used=29.95 L–30 L
Following the calculation, 28.8 kg WD+8.64 kg RD+0.374 kg of limestone+30 L of water were properly mixed in the cultivation and fruiting of mushroom for this study. Thereafter, the substrate was packed into transparent substrate bags of about 0.5 kg which was tightened around an inserted pipe while the hole at the centre of the pipe was closed using foam to prevent contamination.
Thereafter, the bags were moved to the sterilization drum (at a temperature of 199°C) and were heated for 7 hours. Inoculation of the substrate and incubation were carried out concurrently in a constant light and air, and between the temperature of 20°C–25°C in order to achieve optimal fruiting process. This method enabled the mycelia to grow into fruiting bodies. Duration of spawn run was determined by counting the number of days it took the mycelia to completely colonize the substrate.

Mushroom harvesting

The mushrooms were harvested within 2–3 days of maturation and were taken to a herbarium in the Department of Biological Sciences, Alex Ekwueme Federal University Ndufu-Alike, Ikwo, for identification. The mushrooms were assigned a voucher number, AE-FUNAI/2020/167, then sun dried and stored in a refrigerator at 4°C before use.

Quantitative analysis of phytochemicals of Pleurotus cornucopiae

The bioactive components of the aqueous extract of P. cornucopiae was quantitatively analyzed using a vortex mixer set at high speed and HPLC (Agilent 1100 series LC) equipped with column thermostat (Agilent Technologies). Chromatographic separation was done using ZORBAX SB-C18 analytical column (250 mm_4.6 mm, 5 mm) at a wavelength of 257 nm. The procedure as stated by Wang et al. [23] and modified by Aloke et al. [24] was applied.

Test for the basic phytochemicals in Pleurotus cornucopiae extract

The phytochemical screening of the extract using aqueous solvents was carried out to identify each component as described by Harborne [25], and modified by Adebiyi [26].
Flavonoids and phenol: One ml of 10% NaOH solution was added to a solution of 10-ml distill water and 3-ml of the extract. A yellow and orange coloration indicated the presence of flavonoid and phenol respectively [27].
Alkaloid: A solution of 1 ml of 1% HCl acid was added to 3-ml of extract in a test tube, and the mixture was heated in a water bath for 20 minutes. Thereafter, 1 ml of the filtrate from (a) above was added to 0.5 ml of Meyer’s reagent. The creamy colour of the solution indicates the presence of alkaloid [28].
Frothing test for saponin: 3 ml of extract was diluted with 2 ml of distilled water in a test tube. The frothing was mixed with a few drops of olive oil and mixed vigorously and the foam appearance showed the presence of saponins [29].
Salkowski test for steroid: Five drops of concentrated H2SO4 was added to 1-ml of extract in a separate test tube. The presence of red colouration indicated the presence of steroid [28].
Ferric chloride test for tannins: 2-ml of extract were boiled gently in a separate test tube for 2 minutes and allowed to cool. The appearance of a green-coloured precipitate when three drops of ferric chloride solution was added to the solution and mixed vigorously, indicated the presence of tannins [28].
Glycosides: 1 ml of the extract was mixed with 10-ml of 50% H2SO4 in a test tube, and heated in a water bath for 15 minutes. The appearance of a brick red precipitate when 10-ml of Fehling’s solution was added and heated, indicated the presence of glycosides [28].

Aqueous mushroom extraction

Dried mushrooms weighing 217 g were grinded to powder (mesh-size of about 200–2,500) using a milling machine (vertical type; M-4) and the final weight of 204.04 g was obtained. The powder was soaked and constantly agitated in 500 ml of distilled water for 48 hours using a magnetic stirrer (hotplate 78-1; Lasec), and filtered using Whattman filter paper (cat No: 1001110). The filtrate was concentrated using a water bath, at a temperature of 40°C. The stock solution that was used for the experiment was 204 g/68 ml (3 g/ml). The dose given to each rat was determined using the relationship as described by Okolo et al. [9]:
Vol. (ml)=weight (kg) of animal ×dose(mg/kg)stock solution(mg/ml)

Animals and housing

Twenty-five male Wistar rats weighing about 160–200 g were obtained from the animal house of Alex Ekwueme Federal University Ndufu Alike, Nigeria. The rats were housed in standard plastic cages at room temperature and in a 12 hours dark/12 hours light cycle. The rats were allowed to acclimate for 7 days. The animals were carefully handled following the guidelines of the National Institute of Health (NIH) for care and use of laboratory animals [30]. The study was approved by a research and ethics committee of AE-FUNAI with reference number AE-FUNAI/FBMS/EC/AE/2020.

Treatment groups

The rats were divided into 5 groups of with 5 rats as follows; Group 1: normal control (NC): administered distilled water and normal rat choa; Group 2: diabetic control (DC): treated with alloxan monohydrate. Group 3: diabetic rats administered with 5-mg of glibenclamide/kg bwt, for 14 days, to ensure diabetic condition as was previously reported [31]. Group 4: diabetic rats administered P. cornucopiae extract 250 mg/kg bwt; and Group 5: diabetic rats administered P. cornucopiae extract 500 mg/kg bwt. The treatments lasted for 4 weeks.

Induction of diabetes with alloxan

The rats in group 2, 3, 4, and 5 were fasted overnight and an intraperitoneal injection of aqueous alloxan monohydrate (150 mg/kg bwt; CAS 3237-50-1) was dissolved in physiological saline (0.9% NaCl) and administered to the appropriate rat groups at a dose of 150 mg/kg/bwt for 14 days to induce diabetes [32]. The non-fasting blood glucose (FBG) levels of the rats in group 1 were checked after 7 days with the aid of a modern glucometer (Glucoplus Inc.). Rats with blood glucose level above 200 mg/dl were considered to be diabetic. The NC rats were allowed to have access to food and ad libitum. Weekly fasting glucose level was determined throughout the duration of the experiment at intervals of one day.

Choice of diabetogenic agent

Briefly alloxan and streptozotocin (STZ), are commonly employed as diabetogenic agent in diabetes studies. Though their beta cell cytotoxicity is accomplished through different routes, their selective mechanisms of action on pancreatic beta cell are alike (Fig. 1) [33]. Reports show that various authors have used alloxan to induce type 2 diabetes [33-36] and it has been reported that both alloxan and STZ can also be used to induce type1diabetes [34]. Therefore, both alloxan and STZ are used for the induction of type 2 diabetes [37, 38], but alloxan was used in the present study because of its availability [39] and type 2 diabetes was successfully induced.

Animal sacrifice and sample collection

At the end of the treatment, the rats were fasted for 24 hours and were then euthanized with chloroform by placing each in isolated air tight glass jar containing chloroform. Each unconscious rat was placed in a supine position and pinned firmly by its four limbs to the dissecting board and the abnormal region was incised using surgical blade. The blood samples were collected through the orbital sinuses by an intra-orbital puncture using well-labelled plane heparinized capillary glass tube. Blood samples of about 4-ml were collected from each rat and centrifuged (Model: Axiom centrifuge 80-2; Axiom medical Ltd.) at 4,000 rpm for 10 minutes and the sera were obtained for biochemical analysis. The kidneys were harvested and fixed in 10% formalin for histopathology and immune chemical analysis.

Laboratory assessment of oxidative stress makers

Analysis of catalase

The activity of catalase (CAT) was assayed following the method of Sinha [40]. Dichromate in acetic acid was reduced to chromic acetate when heated in the presence of hydrogen peroxide with the formation of per chromic acid as an unstable intermediate. The chromic acetate formed was measured at 590 nm. CAT was allowed to split H2O2 for different periods of time [40]. The reaction was stopped at different time intervals by the addition of dichromate acetic acid mixture and the remaining H2O2 was determined by measuring chromic acetate in a calorimeter after heating the reaction mixture [33]. Serum was pipetted into a tube containing 0.9 ml of phosphate, 0.1 ml of plasma and 0.4 ml of H2O2 added. The reaction was observed for 15, 30, 45, and 60 seconds respectively by adding 2-ml of dichromate acetic acid mixture. The tubes were kept in a boiling water bath for 10 minutes, cooled and the colour developed was read at 530 nm. Standards in the concentration range of 20–100 micro moles were processed for the test. One unit of CAT activity was expressed in Umol/ml of plasma (U-micro moles of H2O2 utilized/second) [41].

Analysis of superoxide dismutase

Superoxide dismutase (SOD) activity was measured according to the method of Fridovich [42]. The principle of the assay was based on the ability of SOD to inhibit the reduction of nitro-blue tetrazolium. Adrenalin (0.01 g) was dissolved in 17 ml of distilled water and 0.1 ml of serum and 0.9 ml of phosphate buffer (pH 7.8) were taken in triplicates in 2.5 ml buffer. A volume of 0.3 ml adrenaline solution was added and mixed inside the cuvette. The absorbance was taken at 480 nm at 30 seconds interval for 5 times. The changing rate of absorbance was used to determine SOD activity and was expressed as units/mg protein [42].

Analysis of malondialdehyde

Malondialdehyde (MDA), an index of lipid peroxidation was determined using a descriptive colorimetric method described by Buege and Aust [43]. The principle was based on the reaction of MDA with thiobarbituric acid producing thiobarbituric acid reactive substance (TBARS), a pink chromogen, which was measured with a spectrophotometer at 532 nm. MDA was calculated using molar extinction coefficient for MDA TBA-complex of 1.56×105 M-1CM-1 and its concentration was expressed as micromole of MDA/gm kidney tissue.

Analysis of glutathione peroxidase

Glutathione peroxidase (GPx) activity was determined spectrophotometrically as described by Ubhenin et al. [44]. The principle was based on the reactions of glutathione reductase and NADPH. The oxidized glutathione was converted to the reduced form with a simultaneous oxidation of NADPH to NADP+. Thereafter, GPx activity was measured at 340 nm by the decrease of NADPH absorbance using extinction coefficient of 6.22 nm expressed in unit/mg-protein.

Assessment of renal function test

Serum urea (normal range; 5–20 mg/dl or 1.8–7.1 mmol/L)

It was determined by the colorimetric method using ddH20 (50 µl) in a new Gain calibration in cuvette mode. Urea was heated with biacytl monoxime in acid solution. The mixture was incubated for 15 minutes at 20°C–25°C into the Rx Monza Flowcell holder and read press for calibration within 30 minutes. Measurement of absorbance of sample (Asample) and standard (Astandard) against reagent blank was done within 30 minutes. Urea exhibit a yellow coloration. Serum creatinine was determined by colorimetric method using ddH20 (50 µl) in a new Gain calibration in cuvette mode. Picric acid (2 ml solution) and 1 ml. of the sodium hydroxide solution were added to 2 ml. of a solution containing 20 ɣ of creatinine. The mixture was allowed to stand until the maximum color had developed. It was mixed into the Rx Monza Flowcell holder and read press for calibration at a temperature of 37°C. For calibration to take place, absorbance A1 and A2 were read after 30 seconds and 2 minutes respectively. Calculation was done using Randox Calibration Serum Level 3. The color developed in both the standard solution and in the reagent blank was determined.

Serum electrolytes

This involved the assessment of Sodium, potassium, chloride and calcium levels using appropriate techniques. This was determined using sodium assay kit (colorimeter) (ab211096) with a sensitivity of 25 µm on a platform of microplate reader. Here, sodium ions present in the assay are used by enzyme β-galactosidase to produce an intermediate product which reacts with a developer to generate a color signal at 405 nm.
Potassium was determined when potassium tetraphenylborate was formed by the reaction between potassium and sodium tetraphenylborate.
Direct method based on a modification of the colorimeter method of Skeggs and Hochstrasser [45] was used to determined chloride level. In this method, chloride ions form a soluble, non-ionized compound with mercuric ions and will displace thiocyanate ions from non-ionized mercuric thiocyanate. The released thiocyanate ions react with ferric ions to form a color complex that absorbs light at 480 nm. The intensity of the color produced is directly proportional to the chloride concentration.
Calcium was evaluated by colorimetric method described by Gran [46]. It involves a convenient and rapid estimation of 5-15-μg Ca in 0.1 ml of blood serum. N-hydroxy-naphtalene-1,8-dicarboxylic acid imide forms an insoluble salt with Ca, which was further mixed into solution by the addition of ethylene diamine tetra-acetic acid in excess. Two moles of N-hydroxy-naphtalene-1,8-dicarboxylic acid imide will be equivalent to one mole of Ca.

Immunohistochemistry

Five-µm thickness of kidney tissue was obtained following tissue processing and routine paraffin preparation for histology. Post paraffinization sections were allowed to heat-mediate antigen retrieval in citrated-based solution, pH 6.0, and endogenous peroxidase blocking was immediately performed in 0.3% hydrogen peroxide. Thereafter, incubation took place overnight at 4°C in primary rat antibodies; Nrf2 (#ab31163; Abcam) at 1:200 and 1:100 dilutions respectively. Secondary incubation was performed in ImmPRESSTM horseradish peroxidase (HRP) Anti-Rat IgG (Peroxidase) Polymer Reagent, made in horse (Vector #MP-7401). 3,3’-Diaminobenzidine (DAB) peroxidase (HRP) Substrate Kit (Vector #SK-4100) was used for colour development, and sections were counter-stained in Harris haematoxylin. Positive control sections were similarly processed without primary antibody incubation. Quantification of immunoreactivity was performed using the ImmunoRatio plugin on ImageJ software (NIH) which separates and quantify percentage of DAB (positive immunoreactivity) by digital color deconvolution [47].

Histology

The fixed kidneys were removed from the 10% formalin fluid and dehydrated using ascending grades of alcohol. The dehydrated tissues were cleared in 2 changes of xylene for 2 hours; The cleared tissues were infiltrated by immersion in molten paraffin wax to allow solidification. The embedded tissues were blocked in rectangular blocks and then the blocks were cut in 5 μm serial sections using a rotary microtome. The tissue sections were allowed to float on water at 30°C to help the spreading of the paraffin ribbons. Tissue sections were placed on clean glass slides. The slides were then left to dry and later stained using hematoxylin and eosin (H&E). The stained tissue was observed with a light microscope. Photomicrographs of these sections were taken with camera (DP74; Olympus Corporation) attached to light microscope (CX21i/MX21i; Chongqing MIC Technology Co., Ltd.).

Statistical analyses

The data was expressed as mean±standard error of the mean, and statistical significance between two groups were considered when P<0.05. Comparison between groups was made by two-way analysis of variance (ANOVA) followed by post-hoc Tukey test. Statistical Package of Social Sciences (SPSS) version 23.0 (IBM Co.) was used.

Results

The result showed that P. cornucopiae found in our locality contains saponin, flavonoid and tannin (Table 1). Table 2, presents the mean body weight of the animals and showed incremental increase in weekly mean body weight of the rats in all the groups, which was significant (P<0.05) only in group 1 (untreated control) in the 2nd, 3rd, and 4th weeks of experiment (Table 2), but there was no significant change in body weight across the treated groups (3, 4, and 5) in comparison with the normal or DC groups (groups 1 and 2).
The results of the FBG levels are presented in Table 3. Variations were recorded on blood glucose levels in all the treated rat groups against the normal (untreated) and positive (diabetic) control groups. The 500 mg/kg/bwt, dose of the extract non-significantly reduced blood glucose level at week 3 compared against glibenclamide and 250 mg bwt of extract. However, both glibenclamide and the extract lowered the blood glucose level of the treated diabetic rats (groups 3, 4, and 5) to similar levels at the end of week 4 (Table 3). This FBG levels were, however, significantly lower compared against the DC group (i.e., group 2).
Tables 4 and 5 show the biochemical analysis of oxidative stress biomarkers, and renal functions markers as well as serum electrolyte levels receptively. In Table 4, there were no significant decrease or increase in CAT, GPx, and MDA activities in treated groups (i.e., groups 3, 4, and 5) compared with DC (i.e., group 2), but significant increases (P<0.05) in mean SOD activity were recorded in groups 3, 4, and 5, with highest increase in 250 mg/kg bwt of P. cornucopiae compared with DC (i.e., group 2) (Table 4). Table 5, showed no significant increase in the mean serum creatinine, urea and electrolytes (Na+ and K+) in the normal (untreated group 1) and DC (i.e., group 2) relative to the treated groups (i.e., groups 3, 4, and 5), However, there was significant different (P<0.05) at 500 mg dose level. The extract at 500 mg/kg bwt non-significantly increased plasma creatine, potassium and calcium levels relative to DC (group 2) as well as groups 3 and 4 (the glibenclamide and 250 mg/kg P. cornucopiae treated groups). Further, while the 250 mg/kg P. cornucopiae treatment non-significantly increased plasma urea against the control groups (i.e., 1 and 2) and Glibenclamide treated group (group 3), the 500 mg/kg P. cornucopiae reduced the urea and sodium levels against all groups. Generally, plasma level of chloride was not affected. Also, the 500 mg/kg P. cornucopiae activated Nrf2 expression more than glibenclamde and 250 mg/kg btw of P. cornucopiae treated rat group (i.e., groups 3 and 4; Fig. 2).
The histology analysis using H&E routine tissue stains are present in Fig. 3. The results show severe degeneration of renal tissue with severe atrophy of the glomeruli, intra renal hemorrhage and severe intra renal inflammation were seen in DC rats (group 2; Fig. 3B) which effects were ameliorated in the treated groups (groups 3, 4, and 5; Fig. 3C–E). The histochemical evaluation of the effects of the treatment using Nrf2, presented in Fig. 4, showed that the 500 mg/kg P. cornucopiae activated Nrf2 expression more than the treated groups (i.e., groups 2, 3, and 4). The quantitative analysis is confirmed through the use of ImageJ software (Fig. 2). The graph shows the percentage immunoreactivity of Nrf2 expression in male Wistar rats with alloxan induced diabetes, and treated with glibenclamide and mushroom (P. cornucopiae); control (group 1) 13.4%, (group 2) alloxan treated (DC) 30%, (group 3) alloxan (diabetes)+glibenclamide 56.6%, (group 4) alloxan (diabetes)+250 mg/kg P. cornucopiae, 54.6%, (group 5) alloxan (diabetes)+500 mg/kg P. cornucopiae 59.8.0%. Furthermore, all the treated groups showed increased expression of Nrf2 compared to the control, while the treated groups (groups 2, 3, and 4) showed non-significant differences in the expression of NrF2 against each other, but group 5 (the alloxan [i.e., diabetic]+500 mg/kg P. cornucopiae) showed significant difference against the rest treated groups (groups 2, 3, and 4; P<0.05).

Discussion

Diabetes is a significant public health problem that is expensive to treat and leads to substantial morbidity and mortality [48] particularly in developing countries with limited health care facilities and very poor accessibility. Diabetes has been reported as a disease of lifestyle [49, 50] and uncoordinated lifestyle is commonplace in rural life, with predominant sedentary lifestyle and very high carbohydrate/calorie diet. Additionally, these rural settings are plagued with very poor quality education both formal and informal, which has contributed to a rise in this non-communicable disease [51-53]. While the prevalence of diabetes is high in Nigeria [7, 54], antidiabetic drugs are unavailable, inaccessible and expensive [55]. The efforts of the Nigerian government to ensure the availability of antidiabetic drugs yielded no desirable results because of poor distribution system, poor quality control and the fundamental bureaucratic nature of the administration. However, the results of the present study showed that this locally available and accessible edible plant mushroom (P. cornucopiae) possess some good antidiabetic properties which could be useful in reducing the high prevalence of diabetes in the locality and beyond.
Contrary to the findings of some authors [56, 57], there was a significant increase in body weight of rats throughout the period of study. Systemic manifestation of diabetes complications often present as weakness, polyphagia, polydipsia and body weight loss, which could be as a result of degeneration of the adipocytes and muscle tissues [58]. Similarly, the studies of Dawang et al. [59]; Akunna et al. [60] reported an increase in body weight of the experimental rats, which was attributed to active growth phase, but the significant increase in body weight in the present study could be attributed to the short period of treatment before the onset of weight loss.
The rats that received P. cornucopiae or glibenclamide had reduced FBG levels at week 4 of treatment when compared with the DC group, suggesting a gradual anti-hyperglycemic effect of both treatments. Further, the result corroborates with the study of Chen et al. [61] which suggested that P. cornucopiae has hypoglycemic properties and could stimulate repair of renal architecture. Although, the extract showed optimum activity in the current study at the dose of 500 mg/kg, the ability of both doses of P. cornucopiae to enhance antioxidant activity was observed by the increased SOD in groups treated with P. cornucopiae of different doses. SOD is an oxidative marker that plays an important role in restoring multiple cellular pathways associated with damage of important biomolecules and subcellular structures in cells by oxidative stress. We clearly observed an improved glucose tolerance in the rats treated with P. cornucopiae suggesting a reversal of hyperglycemia (lowered FBG) which is similar to the studies by Erukainure et al. [62] and Oboh et al. [63].
Diabetes speed-up activities of enzymes in the pathways of glycogenolysis, gluconeogenesis and glycolysis [64-66], and MDA (maker of oxidative damage) is generated by per oxidation of membrane polyunsaturated fatty acids [67]. SOD is an enzyme that alternately catalyzes the dismutation (partitioning) of the superoxide radical into ordinary molecular oxygen and hydrogen peroxide [68]. Thus, SOD is an important antioxidant defense in nearly all living cells exposed to oxygen [69, 70], the current study revealed that glibenclamide and the 250 mg/kg bwt extract did not influence CAT and GPx activities, but appreciably increased SOD and CAT activities more than glibenclamide and 500 mg/kg dose in diabetes. This implies that P. cornucopiae, at appropriate dose possess antidiabetic properties and contribute significantly reduce oxidative associated with diabetes.
The result revealed the presence of saponin, flavonoid and tannin in the extract and saponins have hemolytic properties [71]. Tomato saponin, alpha-tomatine could induce apoptosis and eradicate abnormal and potentially harmful cells [72]. It is possible that the interaction of saponins and other bioactive constituents of P. cornucopiae could potentiate the regeneration of renal tissues, which could explain the observed changes in histopathology.
The result also revealed that extract at 500 mg/kg bwt reduced the plasma urea and sodium concentration in rats with diabetes. These findings were similar to the observations of Hong et al. [73]; Dere and Polat [74]; Vuksa et al. [75]; Attia and Nasr [76]. Kidney failure is associated with increase in plasma creatinin and urea levels, which is due to increase in production of free radicals that exacerbates the nephrodegenerative process of deteriorating renal enzymes as reported by Samai et al. [77]; Akinloye et al. [78] and Smith et al. [79]. Oral administration of the extract at 500 mg/kg body weight for 21 days enhanced renal enzymes and reversal of the renal damage [80].
Nrf2 is an emergent regulator of cellular resistance to oxidants. Numerous mouse genetic studies have demonstrated the beneficial effects of Nrf2 activation on the prevention of kidney disease [81]. The presence of high expression of Nrf2 treated groups D and E, may signal antioxidant regulation across the treated groups, when compared to the DC group. Oxidative stress and inflammation caused by diabetes could lead to glomerular filtration rate decline and severe inflammation of the kidney [82, 83]. In addition, Nrf2 regulates cellular defense against toxic and oxidative insults through expression of genes involved in oxidative stress response and drug detoxification [84, 85].
In conclusion, the drug glibenclamide and P. cornucopiae have appreciable hypoglycemic activity and potential to restore the renal architecture of the rats kidney. Additionally, the extract (at 500 mg/kg bwt) activated the activities of SOD and Nrf2 expression more than glibenclamide in diabetic rats suggesting better efficacy.

Acknowledgements

We wish to acknowledge the management team of Animal House in AE-FUNAI and Nnonna Ifeanyi for handling the rats adequately throughout the period of the study.

Notes

Authors Contributions

Conceptualization: CGU, UKE, MSO, NL. Methodology: CGU, UKE, EC, UO, AJN. Data analysis or interpretation: CGU, UKE. Drafting of the manuscript: CGU, MSO, EG. Manuscript writing: CGU, MSO, UO, UKE. Critical revision of the manuscript: UKE, CGU. Supervision: UKE, CGU. Approval of the final version of the manuscript: all authors.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Sicree R, Shaw J, Zimmet P. Gan D, editor. The global burden. Diabetes and impaired glucose tolerance. Prevalence and projections. Diabetes Atlas. 3rd ed. International Diabetes Federation;2006. p. 16–103.
2. Owembabazi E, Nkomozepi P, Calvey T, Mbajiorgu EF. 2023; Co-administration of alcohol and combination antiretroviral therapy (cART) in male Sprague Dawley rats: a study on testicular morphology, oxidative and cytokines perturbations. Anat Cell Biol. 56:236–51. DOI: 10.5115/acb.22.229. PMID: 36759974. PMCID: PMC10319480.
3. Collins AJ, Kasiske B, Herzog C, Chen SC, Everson S, Constantini E, Grimm R, McBean M, Xue J, Chavers B, Matas A, Manning W, Louis T, Pan W, Liu J, Li S, Roberts T, Dalleska F, Snyder J, Ebben J, Frazier E, Sheets D, Johnson R, Li S, Dunning S, Berrini D, Guo H, Solid C, Arko C, Daniels F, Wang X, Forrest B, Gilbertson D, St Peter W, Frederick P, Eggers P, Agodoa L. 2003; Excerpts from the United States Renal Data System 2003 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 42(6 Suppl 5):A5–7. S1–230. DOI: 10.1053/j.ajkd.2004.10.009. PMID: 14655179.
4. Church DS, Barker P, Burling KA, Shinwari SK, Kennedy C, Smith D, Macfarlane DP, Kernohan A, Stears A, Karamat MA, Whyte K, Narendran P, Halsall DJ, Semple RK. 2023; Diagnosis and treatment of anti-insulin antibody-mediated labile glycaemia in insulin-treated diabetes. Diabet Med. 40:e15194. DOI: 10.1111/dme.15194. PMID: 37562398. PMCID: PMC10946589.
5. Yenet A, Nibret G, Tegegne BA. 2023; Challenges to the availability and affordability of essential medicines in African countries: a scoping review. Clinicoecon Outcomes Res. 15:443–58. DOI: 10.2147/CEOR.S413546. PMID: 37332489. PMCID: PMC10276598.
6. Ugwu E, Young E, Nkpozi M. 2020; Diabetes care knowledge and practice among primary care physicians in Southeast Nigeria: a cross-sectional study. BMC Fam Pract. 21:128. DOI: 10.1186/s12875-020-01202-0. PMID: 32611395. PMCID: PMC7330977.
7. Ogbera AO, Ekpebegh C. 2014; Diabetes mellitus in Nigeria: the past, present and future. World J Diabetes. 5:905–11. DOI: 10.4239/wjd.v5.i6.905. PMID: 25512795. PMCID: PMC4265879.
8. Uloko AE, Musa BM, Ramalan MA, Gezawa ID, Puepet FH, Uloko AT, Borodo MM, Sada KB. 2018; Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. Diabetes Ther. 9:1307–16. DOI: 10.1007/s13300-018-0441-1. PMID: 29761289. PMCID: PMC5984944.
9. Okolo KO, Siminialayi IM, Orisakwe OE. 2016; Protective effects of Pleurotus tuber-regium on carbon- tetrachloride induced testicular injury in Sprague Dawley rats. Front Pharmacol. 7:480. DOI: 10.3389/fphar.2016.00480. PMID: 28018218. PMCID: PMC5156682.
10. Golak-Siwulska I, Kałużewicz A, Spiżewski T, Siwulski M, Sobieralski K. 2018; Bioactive compounds and medicinal properties of Oyster mushrooms (Pleurotus sp.). Folia Hortic. 30:191–201. DOI: 10.2478/fhort-2018-0012.
11. Izham I, Avin F, Raseetha S. 2022; Systematic review: heat treatments on phenolic content, antioxidant activity, and sensory quality of Malaysian mushroom: oyster (Pleurotus spp.) and black jelly (Auricularia spp.). Front Sustain Food Syst. 6:882939. DOI: 10.3389/fsufs.2022.882939.
12. Khan MA, Tania M. 2012; Nutritional and medicinal importance of Pleurotus mushrooms: an overview. Food Rev Int. 28:313–29. DOI: 10.1080/87559129.2011.637267.
13. Joshi M, Sagar A. 2014; In vitro free radical scavenging activity of a wild edible mushroom, Sparassis crispa (Wulf.) Fr., from North Western Himalayas, India. J Mycol. 2014:748531. DOI: 10.1155/2014/748531.
14. Wasser SP. 2014; Medicinal mushroom science: current perspectives, advances, evidences, and challenges. Biomed J. 37:345–56. DOI: 10.4103/2319-4170.138318. PMID: 25179726.
15. Lindequist U, Niedermeyer TH, Jülich WD. 2005; The pharmacological potential of mushrooms. Evid Based Complement Alternat Med. 2:285–99. DOI: 10.1093/ecam/neh107. PMID: 16136207. PMCID: PMC1193547.
16. Guillamón E, García-Lafuente A, Lozano M, D'Arrigo M, Rostagno MA, Villares A, Martínez JA. 2010; Edible mushrooms: role in the prevention of cardiovascular diseases. Fitoterapia. 81:715–23. DOI: 10.1016/j.fitote.2010.06.005. PMID: 20550954.
17. Farquhar WB, Edwards DG, Jurkovitz CT, Weintraub WS. 2015; Dietary sodium and health: more than just blood pressure. J Am Coll Cardiol. 65:1042–50. DOI: 10.1016/j.jacc.2014.12.039. PMID: 25766952. PMCID: PMC5098396.
18. Elsayed EA, El Enshasy H, Wadaan MA, Aziz R. 2014; Mushrooms: a potential natural source of anti-inflammatory compounds for medical applications. Mediators Inflamm. 2014:805841. DOI: 10.1155/2014/805841. PMID: 25505823. PMCID: PMC4258329.
19. Okolo KO, Orisakwe OE. 2020; In vitro antioxidants and hepatoprotective effects of Pleurotus tuber-regium on carbon tetrachloride-treated rats. J Basic Clin Physiol Pharmacol. 32:67–78. DOI: 10.1515/jbcpp-2020-0034. PMID: 32833668.
20. Rajasekaran S, Sivagnanam K, Subramanian S. 2005; Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats. Pharmacol Rep. 57:90–6. DOI: 10.1211/0022357055416. PMID: 15849382.
21. Gray AM, Flatt PR. 1998; Insulin-releasing and insulin-like activity of Agaricus campestris (mushroom). J Endocrinol. 157:259–66. DOI: 10.1677/joe.0.1570259. PMID: 9659289.
22. Okigbo RN, Ezebo RO, Nwatu CM, Omumuabuike JN, Esimai GB. 2021; A study on cultivation of indigenous mushrooms in South Eastern Nigeria. World News Nat Sci. 34:154–64.
23. Wang H, Gao J, Ng TB. 2000; A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom Pleurotus ostreatus. Biochem Biophys Res Commun. 275:810–6. DOI: 10.1006/bbrc.2000.3373. PMID: 10973803.
24. Aloke C, Emelike CU, Obasi NA, Ogbu PN, Edeogu CU, Uzomba GC, Ekakitie O, Iyaniwura AA, Okoro CC, Okey BP, Aninjoku GG, Ushahemba BC. 2021; HPLC profiling and studies on Copaifera salikounda methanol leaf extract on phenylhydrazine-induced hematotoxicity and oxidative stress in rats. Arabian J Chem. 14:103428. DOI: 10.1016/j.arabjc.2021.103428.
25. Harborne JB. Phytochemical methods. 3rd ed. Chapman and Hall Ltd;1993. p. 49–188.
26. Adebiyi AO. 2018; Distribution of phytochemicals and some anti-nutrients in selected edible mushrooms in Ekiti State, Nigeria. Int J Sci Eng Invent. 2018:10–3. DOI: 10.23958/10.23958/ijsei/vol04-i09/88.
27. Wong F, Chai TT, Tan SL, Yong AL. 2013; Evaluation of bioactivities and phenolic content of selected edible mushrooms in Malaysia. Trop J Pharm Res. 12:1011–6. DOI: 10.4314/tjpr.v12i6.21.
28. Yılmaz A, Yıldız S, Kılıç C, Can Z. 2017; Total phenolics, flavonoids, tannin contents and antioxidant properties of Pleurotus ostreatus cultivated on different wastes and sawdust. Int J Sec Metab. 4:1–9. DOI: 10.21448/ijsm.252052.
29. Gul R, Jan SU, Faridullah S, Sherani S, Jahan N. 2017; Preliminary phytochemical screening, quantitative analysis of alkaloids, and antioxidant activity of crude plant extracts from Ephedra intermedia indigenous to Balochistan. ScientificWorldJournal. 2017:5873648. DOI: 10.1155/2017/5873648. PMID: 28386582. PMCID: PMC5366796.
30. National Research Council. Guide for the care and use of laboratory animals. 6th ed. National Institutes of Health;1985. p. 85–123.
31. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. 2015; Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ. 350:h102. DOI: 10.1136/bmj.h102. PMID: 25609400. PMCID: PMC4301599.
32. Njogu SM, Arika WM, Machocho AK, Ngeranwa JJN, Njagi ENM. 2018; In vivo hypoglycemic effect of Kigelia africana (Lam): studies with alloxan-induced diabetic mice. J Evid Based Integr Med. 23:2515690X18768727. DOI: 10.1177/2515690X18768727. PMID: 29651878. PMCID: PMC5901018.
33. Lenzen S. 2008; The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 51:216–26. DOI: 10.1007/s00125-007-0886-7. PMID: 18087688.
34. Singh R, Gholipourmalekabadi M, Shafikhani SH. 2024; Animal models for type 1 and type 2 diabetes: advantages and limitations. Front Endocrinol (Lausanne). 15:1359685. DOI: 10.3389/fendo.2024.1359685. PMID: 38444587. PMCID: PMC10912558.
35. Rahman SS, Yasmin N, Rahman ATMM, Zaman A, Rahman MH, Rouf SMA. 2017; Evaluation and optimization of effective-dose of alloxan for inducing type-2 diabetes mellitus in Long Evans rat. Indian J Pharm Educ Res. 51(4 Suppl):S661–6. DOI: 10.5530/ijper.51.4s.96.
36. Devaki K, Beulah U, Akila G, Narmadha R, Gopalakrishnan VK. 2011; Glucose lowering effect of aqueous extract of Bauhinia tomentosa L. on alloxan induced type 2 diabetes mellitus in wistar albino rats. J Basic Clin Pharm. 2:167–74. PMID: 24826019. PMCID: PMC3979230.
37. Maroof K, Gan SH. Boyacioglu D, editor. Bee products and diabetes mellitus. Bee Products and Their Applications in the Food and Pharmaceutical Industries. Academic Press;2022. p. 63–114. DOI: 10.1016/B978-0-323-85400-9.00012-5.
38. Fajarwati I, Solihin DD, Wresdiyati T, Batubara I. 2023; Self-recovery in diabetic Sprague Dawley rats induced by intraperitoneal alloxan and streptozotocin. Heliyon. 9:e15533. DOI: 10.1016/j.heliyon.2023.e15533. PMID: 37159693. PMCID: PMC10163600.
39. Kottaisamy CPD, Raj DS, Prasanth Kumar V, Sankaran U. 2021; Experimental animal models for diabetes and its related complications-a review. Lab Anim Res. 37:23. DOI: 10.1186/s42826-021-00101-4. PMID: 34429169. PMCID: PMC8385906.
40. Ighodaro OM, Adeosun AM, Akinloye OA. 2017; Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 53:365–74. DOI: 10.1016/j.medici.2018.02.001. PMID: 29548636.
41. Sinha AK. 1972; Colorimetric assay of catalase. Anal Biochem. 47:389–94. DOI: 10.1016/0003-2697(72)90132-7. PMID: 4556490.
42. Fridovich I. 1989; Superoxide dismutases. An adaptation to a paramagnetic gas. J Biol Chem. 264:7761–4. DOI: 10.1016/S0021-9258(18)83102-7. PMID: 2542241.
43. Buege JA, Aust SD. 1978; Microsomal lipid peroxidation. Methods Enzymol. 52:302–10. DOI: 10.1016/S0076-6879(78)52032-6. PMID: 672633.
44. Ubhenin AE, Adamude FA, Nweze CC, Dingwoke EJ. 2019; Protective effects of Pleurotus ostreatus in ameliorating carbon tetrachloride (ccl4) induced liver injury in Wistar rats. J Med Plants Res. 13:104–11. DOI: 10.5897/JMPR2018.6714.
45. Skeggs LT Jr, Hochstrasser H. 1964; Multiple automatic sequential analysis. Clin Chem. 10:918–36. DOI: 10.1093/clinchem/10.10.918. PMID: 14228271.
46. Gran FC. 1960; A colorimetric method for the determination of calcium in blood serum. Acta Physiol Scand. 49:192–7. DOI: 10.1111/j.1748-1716.1960.tb01943.x. PMID: 13828859.
47. Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J. 2010; ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 12:R56. DOI: 10.1186/bcr2615. PMID: 20663194. PMCID: PMC2949645.
48. 2014. Mar. 31. World health statistics [Internet]. World Health Organization;Available from: https://www.who.int/docs/default-source/gho-documents/world-health-statistic-reports/world-health-statistics-2014.pdf. cited 2024 Mar 12.
49. Olokoba AB, Obateru OA, Olokoba LB. 2012; Type 2 diabetes mellitus: a review of current trends. Oman Med J. 27:269–73. DOI: 10.5001/omj.2012.68. PMID: 23071876. PMCID: PMC3464757.
50. Galaviz KI, Narayan KMV, Lobelo F, Weber MB. 2015; Lifestyle and the prevention of type 2 diabetes: a status report. Am J Lifestyle Med. 12:4–20. DOI: 10.1177/1559827615619159. PMID: 30202378. PMCID: PMC6125024.
51. Fazal F, Shahani HA, Gondal MF, Tanveer U, Haider M, Us Sabah N, Shahzad F, Ur Rehman ME. 2023; Attitudes and factors determining the practice of routine medical checkups in the people of Rawalpindi, Pakistan: a cross-sectional study. Cureus. 15:e38843. DOI: 10.7759/cureus.38843. PMID: 37303352. PMCID: PMC10256253.
52. Ojong IN, Nsemo AD, Aji P. 2020; Routine medical checkup knowledge, attitude and practice among health care workers in a tertiary health facility in Calabar, Cross River State, Nigeria. Glob J Health Sci. 12:27–37. DOI: 10.5539/gjhs.v12n8p27.
53. Oshio T, Kan M. 2019; Educational level as a predictor of the incidences of non-communicable diseases among middle-aged Japanese: a hazards-model analysis. BMC Public Health. 19:852. DOI: 10.1186/s12889-019-7182-6. PMID: 31262277. PMCID: PMC6604183.
54. Adijat OA, Folakemi E, Adejumo A, Atolagbe JE. 2021; The prevalence and risk factors of diabetes mellitus among civil service workers in Osogbo, Osun State, Nigeria. J Hypertens Manag. 7:062. DOI: 10.23937/2474-3690/1510062.
55. Tella EE, Yunusa I, Hassan JH, Chindo IA, Oti VB. 2021; Prevalence, contributing factors and management strategies (self-management education) of type 2 diabetes patients in Nigeria: a review. Int J Diabetes Clin Res. 8:148. DOI: 10.23937/2377-3634/1410148.
56. Ibrahim MA, Habila JD, Koorbanally NA, Islam MS. 2016; Butanol fraction of Parkia biglobosa (Jacq.) G. Don leaves enhance pancreatic β-cell functions, stimulates insulin secretion and ameliorates other type 2 diabetes-associated complications in rats. J Ethnopharmacol. 183:103–11. DOI: 10.1016/j.jep.2016.02.018. PMID: 26911526.
57. Okon U, Owo D, Udokang N, Udobang J, Ekpenyong C. 2012; Oral administration of aqueous leaf extract of Ocimum gratissimum ameliorates polyphagia, polydipsia and weight loss in streptozotocin-induced diabetic rats. Am J Med Med Sci. 2:45–9. DOI: 10.5923/j.ajmms.20120203.04.
58. Bindhu MR, Sathe V, Umadevi M. 2013; Synthesis, characterization and SERS activity of biosynthesized silver nanoparticles. Spectrochim Acta A Mol Biomol Spectrosc. 115:409–15. DOI: 10.1016/j.saa.2013.06.047. PMID: 23867642.
59. Dawang NS, AbdulHameed A, Ezra GA. 2010; Phytodiversity of three habitat types in Amurum forest: an important bird area in Jos, Nigeria. Afr J Nat Sci. 13:85–94.
60. Akunna GG, Saalu LC, Ogunlade B, Akingbade AM. 2013; Tackling infertility with medicinal plant: another instance. Glob J Med Plant Res. 1:93–105.
61. Chen RR, Liu ZK, Liu F, Ng TB. 2015; Antihyperglycaemic mechanisms of an aceteoside polymer from rose flowers and a polysaccharide-protein complex from abalone mushroom. Nat Prod Res. 29:558–61. DOI: 10.1080/14786419.2014.952230. PMID: 25200621.
62. Erukainure OL, Okafor O, Ajayi A, Obode O, Ogunji A, Okporua T, Suberu Y, Oke O, Ozumba A, Oluwole O, Elemo G. 2015; Developed beverage from roselle calyx and selected fruits modulates β-cell function, improves insulin sensitivity, and attenuates hyperlipidaemia in diabetic rats. Beni-Suef Univ J Basic Appl Sci. 4:307–13. DOI: 10.1016/j.bjbas.2015.11.007.
63. Oboh H, Obahiagbon F, Osagie A, Omotosho A. 2011; Glycemic response of some local Nigerian drinks in healthy subjects. Niger J Nutr Sci. 32:79–84. DOI: 10.4314/njns.v32i1.67819.
64. Clore JN, Stillman J, Sugerman H. 2000; Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes. 49:969–74. DOI: 10.2337/diabetes.49.6.969. PMID: 10866049.
65. Guo X, Li H, Xu H, Woo S, Dong H, Lu F, Lange AJ, Wu C. 2012; Glycolysis in the control of blood glucose homeostasis. Acta Pharm Sin B. 2:358–67. DOI: 10.1016/j.apsb.2012.06.002.
66. Islam MS, Choi H. 2007; Green tea, anti-diabetic or diabetogenic: a dose response study. Biofactors. 29:45–53. DOI: 10.1002/biof.5520290105. PMID: 17611293.
67. Esterbauer H, Schaur RJ, Zollner H. 1991; Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 11:81–128. DOI: 10.1016/0891-5849(91)90192-6. PMID: 1937131.
68. Kangralkar VA, Patil SD, Bandivadekar RM. 2010; Oxidative stress and diabetes: a review. Int J Pharm Appl. 1:38–45.
69. Landis GN, Tower J. 2005; Superoxide dismutase evolution and life span regulation. Mech Ageing Dev. 126:365–79. DOI: 10.1016/j.mad.2004.08.012. PMID: 15664623.
70. Chelikani P, Fita I, Loewen PC. 2004; Diversity of structures and properties among catalases. Cell Mol Life Sci. 61:192–208. DOI: 10.1007/s00018-003-3206-5. PMID: 14745498. PMCID: PMC11138816.
71. AlSaadi BH, AlHarbi SH, Ibrahim SRM, El-Kholy AA, El-Agamy DS, Mohamed GA. 2018; Hepatoprotective activity of costus speciosus (Koen ex. Retz.) against paracetamol-induced liver injury in mice. Afr J Tradit Complement Altern Med. 15:35–41. DOI: 10.21010/ajtcamv15i2.5.
72. Ezemagu UK, Akunna GG, Egwu OA, Uzomba GC, Nwite KN. 2019; Comparing Ficus vogelii leaf extract and Omeprazole as therapy and prophylaxis for aspirin-induced gastric ulcer in Wistar rat. Biomed Res. 30:697–703. DOI: 10.35841/biomedicalresearch.30-19-195.
73. Hong X, Chi Z, Liu G, Huang H, Guo S, Fan J, Lin X, Qu L, Chen R, Wu L, Wang L, Zhang Q, Wu S, Pan Z, Lin H, Zhou Y, Zhang Y. 2020; Characteristics of renal function in patients diagnosed with COVID-19: an observational study. Front Med. 7:409. DOI: 10.3389/fmed.2020.00409. PMID: 32754610. PMCID: PMC7365839.
74. Dere E, Polat F. 2001; The effect of paraquat on the activity of some enzymes in different tissues of mice (Mus musculus - Swiss albino). Turk J Biol. 25:323–32.
75. Vuksa M, Nesković N, Vitorović S, Karan V. 1983; Subacute toxicity of paraquat in rats--biochemical effects. Ecotoxicol Environ Saf. 7:475–83. DOI: 10.1016/0147-6513(83)90087-8. PMID: 6641584.
76. Attia AM, Nasr HM. 2009; Dimethoate-induced changes in biochemical parameters of experimental rat serum and its neutralization by black seed (Nigella sativa L.) oil. Slovak J Anim Sci. 42:87–94.
77. Samai M, Samai HH, Hague T, Naughton D, Chatterjee PK. 2010; Novel superoxide dismutase mimetics for protection against Paraquat-induced acute renal injury. Sierra Leone J Biomed Res. 2:54–64. DOI: 10.4314/sljbr.v2i1.56608.
78. Akinloye OA, Adamson I, Ademuyiwa O, Arowolo TA. 2011; Supplementation of vitamins C, E and its combination on paraquat-intoxicated rats: effects on some biochemical and markers of oxidative stress parameters. J Appl Pharm Sci. 1:85–91.
79. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, Krumholz HM. 2006; Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med. 166:1134–42. DOI: 10.1001/archinte.166.10.1134. PMID: 16717177.
80. Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, Hernandez BY, Lynch CF, Pawlish K, Engels EA. 2016; Risk of renal cell carcinoma among kidney transplant recipients in the United States. Am J Transplant. 16:3479–89. DOI: 10.1111/ajt.13862. PMID: 27160653. PMCID: PMC5104677.
81. Zhao S, Ghosh A, Lo CS, Chenier I, Scholey JW, Filep JG, Ingelfinger JR, Zhang SL, Chan JSD. 2018; Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice. Endocrinology. 159:836–52. DOI: 10.1210/en.2017-00752. PMID: 29211853. PMCID: PMC5774246.
82. Heiss EH, Schachner D, Werner ER, Dirsch VM. 2009; Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels. J Biol Chem. 284:31579–86. DOI: 10.1074/jbc.M109.009175. PMID: 19797052. PMCID: PMC2797228.
83. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND. 2013; Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant. 28:2038–45. DOI: 10.1093/ndt/gft022. PMID: 23512109. PMCID: PMC3765021.
84. Fahey JW, Zalcmann AT, Talalay P. 2001; The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 56:5–51. DOI: 10.1016/S0031-9422(00)00316-2. PMID: 11198818.
85. Rushmore TH, Kong AN. 2002; Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab. 3:481–90. DOI: 10.2174/1389200023337171. PMID: 12369894.

Fig. 1
Pathways of toxicity alloxan and streptozotocin in beta cells, leading to diabetes induction. Adapted from Lenzen. Diabetologia 2008;51:216-26, with permission [33].
acb-57-3-446-f1.tif
Fig. 2
Fruiting bodies of Pleurotus cornucopiae grown at animal house, AE-FUNAI.
acb-57-3-446-f2.tif
Fig. 3
Photomicrograph of the rat kidney treated with the kidney sections are shown in 10× magnification stained with haematoxylin and eosin. Group (A) control with normal kidney histology with glomerulus (G), intact Bowman’s capsule, proximal convoluted tubules (PCT), distal convoluted tubules (DCT). No capillary congestion, haemorrhage, and interstitial damage. (B) Diabetic group with necrotic glomeruli (NG), generally distorted renal tubular arrangement, undefined proximal, distal convoluted tubules, interstitial damage, capillary congestion, and hemorrhages (H). (C) Standard drug group with white arrowheads showing urinary space shrinkage, NG, normal proximal and distal convoluted tubules (PCT, DCT). (D) Low dose group with several NG, distorted proximal and distal convoluted tubules, interstitial damage (asterisk), inflammations (red bold arrows), atrophied glomerulus (AG). (E) High dose group regenerating glomeruli (black arrows) with Bowman’s capsules, tubular regeneration with well-defined proximal, distal convoluted tubules and resolving interstitial damage, capillary congestion, and hemorrhages, showing protection in this group. BS, Bowman’s space.
acb-57-3-446-f3.tif
Fig. 4
Immunohistochemistry photomicrographs (500× magnification) of Nfr2 expression in kidney tissue of male wistar rats in diabetes, and treated with glibenclamide and mushroom (Pleurotus cornucopiae) magnification ×400. (A) Control (group 1), (B) diabetic control (group 2), (C) diabetic rats+Glibenclamide (group 3), (D) diabetic rats+250 mg/kg P. cornucopiae (group 4), (E) diabetic rats+500 mg/kg P. cornucopiae (group 5). Red arrow shows the expression of Nrf2. Appearance of brown yellow staining in cytoplasm of renal tubular cells in group 1. Positive nuclear staining was observed in groups 3, 4, and 5 indicating regeneration of glomeruli (red arrows) with Bowman’s capsules, tubular regeneration with well-defined proximal, distal convoluted tubules and resolving interstitial damage, capillary congestion and hemorrhages, showing protection in this group. An indication regeneration of glomeruli (red arrows) with Bowman’s capsules, tubular regeneration with well-defined proximal, distal convoluted tubules and resolving interstitial damage, capillary congestion and hemorrhages, showing protection in this group. aStatistically (P<0.05) significant mean difference with normal control.
acb-57-3-446-f4.tif
Table 1
Qualitative analysis of aqueous extract of Pleurotus cornucopiae
Parameters Water
Alkaloid
Saponin +
Flavonoid +
Steriod
Tannin +
Glycosides
Phenol

–, absence; +, presence/trace.

Table 2
Weekly mean weight (g) of male Wistar rats with alloxan induced diabetes, and treated with glibenclamide and mushroom (Pleurotus cornucopiae)
Weeks Control (group 1) Diabetic control
(group 2)
Diabetes+glibenclamide (group 3) Diabetes+250 mg/kg
P. cornucopiae (group 4)
Diabetes+500 mg/kg
P. cornucopiae (group 5)
Week 1 156.6±2.11 212.7±20.62 214.8±17.41 176.3±8.19 187.8±10.91
Week 2 195.5±2.72* 197.6±23.97 212.8±19.36 172.2±4.73 199.7±14.62
Week 3 206.3±4.13* 226.3±34.52 237.8±19.50 178.8±10.31 202.8±14.82
Week 4 206.4±15.53* 250.8±43.85 264.8±15.33 181.6±22.37 209.1±12.02

Values are presented as mean±standard error of the mean. Comparison of weekly mean weights, values in the same row with same superscripts are not significantly different (P>0.05). *Asterisks indicates significant difference in mean weight of control group animals in weeks 2, 3, and 4 compared with that of week 1.

Table 3
Fasting glucose level (mg/dl) of male diabetic Wistar rats treated with glibenclamide and mushroom (Pleurotus cornucopiae)
Weeks Control (group 1) Diabetic control
(group 2)
Diabetes+glibenclamide (group 3) Diabetes+250 mg/kg
P. cornucopiae (group 4)
Diabetes+500 mg/kg
P. cornucopiae (group 5)
Week 1 68.20±7.61 76.20±5.51 66.00±3.80 70.60±5.98 81.20±10.91
Week 2 101.80±7.11 211.20±29.16b 259.20±44.41b 315.50±72.60a 371.00±92.93a
Week 3 93.50±5.49 360.70±95.92c 313.60±74.28c 354.00±75.75c 292.50±68.07c
Week 4 85.00±7.38 406.30±63.83b 229.20±48.04a 234.30±59.84a 229.80±50.68a

Values are presented as mean±standard error of the mean. a,b,cShows significant difference across rows in the groups. In all treatment groups: values in the same row with different superscripts (a vs. b) are significantly different (P<0.05, P<0.001). Whilst values in the same row with similar subscripts are not significantly difference (P>0.05). In week 3, there is relative decrease in all treated groups compared to group 2. FBG level in groups 2, 3, and 4 significantly decreased relative to group 2 (P<0.001) in week 4. FBG, fasting blood glucose.

Table 4
Biochemical analysis of oxidative stress biomarkers of male Wistar rats with alloxan induced diabetes, and treated with glibenclamide and Pleurotus cornucopiae
Biochemical variables Control (group 1) Diabetic control
(group 2)
Diabetes+glibenclamide (group 3) Diabetes+250 mg/kg
P. cornucopiae (group 4)
Diabetes+500 mg/kg
P. cornucopiae (group 5)
CAT (U/m) 691.40±74.97 922.70±21.99a 740.80±61.81a 799.40±153.30a 810.4±70.97a
GPx (U/m) 72.50±8.04 64.17±0.01a 50.83±5.20a 59.31±3.51a 64.17±3.37a
MDA (U/m) 0.253±0.01 0.287±0.01a 0.267±0.03a 0.296±0.03a 0.246±0.01a
SOD (U/L) 82.84±5.84 49.75±14.36a 73.08±13.05b 117.20±28.98b 99.50±43.09b

Values are presented as mean±standard error of the mean. For all parameters: values in the same row with similar a are not significantly different (P>0.05). Whilst values with superscriptbshow significantly different (P<0.05) to diabetic control. CAT and GPx in treatments groups 3, 4, and 5 are relatively decreased to diabetic group. In SOD, treatments groups with P. cornucopiae (groups 4 and 5) show significant increased relatively to group 2 (P<0.001). CAT, catalase; GPx, glutathione peroxidase; MDA, malondialdehyde; SOD, superoxide dismutase.

Table 5
Renal function test of male Wistar rats with alloxan induced diabetes, and treated with glibenclamide and mushroom (Pleurotus cornucopiae)
Renal function test Control (group 1) Diabetic control
(group 2)
Diabetes+glibenclamide (group 3) Diabetes+250 mg/kg
P. cornucopiae (group 4)
Diabetes+500 mg/kg
P. cornucopiae (group 5)
Creatinine (mg/dl) 0.358±0.10a 0.559±0.04a 0.377±0.12a 0.256±0.07a 1.313±0.56b
Urea (mm/L) 1.661±0.17a 3.260±1.18a 2.199±0.58a 3.610±1.03a 1.328±0.07b
K+ (ppm) 4.515±1.02a 4.447±0.94a 6.456±2.18a 4.536±2.19a 6.677±0.07a
Na+ (ppm) 60.00±14.43a 82.50±25.96a 58.18±16.16a 89.09±25.01a 49.74±12.08c
Ca+ (ppm) 0.922±0.42a 0.508±0.23a 0.836±0.39a 0.696±0.32a 1.282±0.48b
Cl- (m/L) 0.584±0.16a 0.581±0.07a 0.468±0.11a 0.571±0.09a 0.539±0.08a

For all the parameters: the values in the rows and colunms with subscript a,b,cShow no significant difference (P>0.05) in the mean serum creatinine, urea and electrolytes of the rats in control and treatment groups.

TOOLS
Similar articles